Kyowa Kirin is a fast-growing global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines in four disease areas: bone and mineral; intractable hematologic; hematology oncology; and rare disease.
Kyowa Kirin Pharmaceutical Development, Inc. (KKD) is a wholly owned subsidiary of Kyowa Kirin USA Holdings, Inc., an industry leader born from the merger of Kyowa Hakko Group and Kirin Group. Backed by six decades of its parent companies’ experience, KKD specializes in the development of new chemical entities and biopharmaceutical therapies. Among other achievements, scientists and collaborators at KKD have leveraged advances in antibody therapeutics to make tremendous strides across key scientific fields, including oncology, immunology and nephrology.
KKD is headquartered in Princeton, New Jersey.